Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash Flows From Operating Activities:
Net loss	$ (14,094,000)	$ (9,005,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	346,000	305,000
Change in fair value of contingent consideration	(257,000)	0
Depreciation	60,000	74,000
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	780,000	285,000
Right of use asset	137,000	123,000
Accounts payable	(504,000)	368,000
Accrued expenses	(326,000)	85,000
Accrued employee benefits	271,000	(147,000)
Lease liability	(127,000)	(168,000)
Net Cash Used In Operating Activities	(13,714,000)	(8,080,000)
Cash Flows from Investing Activities
Purchase of property and equipment	(25,000)	(14,000)
Cash paid for business combination; net of cash acquired	(3,863,000)	0
Pre-acquisition loan to VCN	(417,000)	0
Net Cash Used in Investing Activities	(4,305,000)	(14,000)
Cash Flows from Financing Activities
Payment of VCN's CDTI loan	(1,376,000)	0
Proceeds from "at the market" stock issuance	0	65,960,000
Proceeds from issuance of common stock for warrant exercises	0	8,042,000
Net Cash Provided by Financing Activities	1,358,000	74,002,000
Effects of FX on cash	(84,000)	0
Net (decrease) increase in cash and cash equivalents and restricted cash	(16,661,000)	65,908,000
Cash and cash equivalents and restricted at the beginning of this period	67,325,000	6,227,000
Cash and cash equivalents and restricted cash at the end of this period	50,580,000	72,135,000
Reconciliation of cash, cash equivalents, and restricted cash reported in the statement of financial position
Cash and cash equivalents	50,490,000	72,135,000
Restricted cash included in other long-term assets	90,000	0
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	50,580,000	72,135,000
Supplemental non-cash investing and financing activities:
Fair value of contingent consideration issued in a business combination	12,158,000	0
Fair value of equity issued as consideration in a business combination	6,599,000	0
Effective settlement of pre-closing VCN financing	417,000	0
Goodwill measurement period adjustment	(884,000)	0
In-process R&D measurement period adjustment	810,000	0
Deferred tax liability measurement period adjustment	202,000	0
Effect of warrant exercise price adjustment	340,000	0
Effect of Series A Preferred Stock price adjustment	0	7,402,000
Right of use asset from operating lease	0	1,270,000
Conversion of Series B Preferred Stock	0	2,477,000
Deemed dividends for accretion of Series B Preferred Stock discount	0	1,497,000
In-kind dividends paid in preferred stock	0	24,000
Series C convertible preferred stock
Cash Flows from Financing Activities
Proceeds from sale of series preferred stock, net of issuance cost	2,006,000	0
Series D convertible preferred stock
Cash Flows from Financing Activities
Proceeds from sale of series preferred stock, net of issuance cost	$ 728,000	$ 0